




REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF FINANCE
BUREAU OF INTERNAL REVENUE



28 July 2022

REVENUE MEMORANDUM CIRCULAR NO. 119-2022

SUBJECT : Publishing the Full Text of the July 20, 2022 Letter from the Food and Drug Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Medicines Under Republic Act (R.A.) No. 11534 Known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act

TO : All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the July 20, 2022 letter (Annex "A") from Dr. Oscar G. Gutierrez, Jr., OIC-Director General of the FDA, for the inclusion of 150 mg + 100 mg Nirmatrelvir + Ritonavir film-coated tablet to the List of VAT-Exempt Medicines Under R.A. No. 11534 (CREATE Act) prescribed for COVID-19 treatment.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall take effect on the date of publication by the FDA of the updates to the said list.

All concerned are hereby enjoined to be guided accordingly and give this Circular as wide a publicity as possible.

Lilia C. Guillermo
LILIA CATRIS GUILLERMO
Commissioner of Internal Revenue

000339